News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Boston Scientific stock has fallen about 50% over the past year, yet valuation checks and an intrinsic value estimate based on a Discounted …
Sharemaestro market context Price below Trend Line 52 weeks -55.4% · Next-week setup negative 44.4%Alan Fournier, founder of Pennant Capital Management, made significant portfolio adjustments in Q2 2026, as revealed in his latest 13F filing. His most notable move was the complete liquidation of his Core Scientific Inc (NASDAQ:CORZ) stake, impacting his portfolio by -4.6%. Conversely, he initiated …
Ciena Corp (CIEN) shares recently dropped 3.2% to $428.77, yet GuruFocus assesses the stock as significantly overvalued with a GF Value™ of $99.71. The company has a GF Score™ of 72/100, indicating above-average performance with strong financial strength and growth, but a poor valuation …
Ciena (NYSE:CIEN) shares dropped 3.1% during mid-day trading, despite strong analyst sentiment with a "Moderate Buy" consensus and an average price target of $530.56. The company recently exceeded quarterly earnings expectations, reporting EPS of $1.64 against an expected $1.46 and revenue of $1.57 billion, …
Twist Bioscience Corp (TWST) shares dropped by 5.4% to $118.57, yet the stock is considered 126.4% overvalued compared to its GF Value™ of $52.38. Despite a strong growth rank of 10/10, the company's profitability and valuation ranks are low, coupled with significant insider selling …
An investor group comprising Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. has reported a beneficial ownership of 9.99% in Alto Neuroscience (ANRO). This ownership, totaling 4,176,711 shares, includes common stock and pre-funded warrants, with the exercise of warrants capped …
Core Scientific has announced the completion of its acquisition of Polaris DS LLC for approximately $444 million in cash, securing about 440 MW of gross power capacity. This acquisition advances Core Scientific's plan to expand its Muskogee campus to 1.5 GW of gross power, …
Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have reported a beneficial ownership of 1,489,443 shares of Inhibrx Biosciences, Inc. (INBX) common stock, representing 9.99% of the class. This stake includes common shares and pre-funded warrants, with the exercise of …
ADAR1 Capital Management, LLC and Daniel Schneeberger have disclosed a 2.5% beneficial ownership stake in Spruce Biosciences, Inc. (SPRB) through a SCHEDULE 13G/A filing. This stake, totaling 67,717 shares, is held across various managed accounts, with both parties exercising shared voting and dispositive power. …
Valiant Capital, along with its entities and Christopher R. Hansen, has disclosed a 5.3% beneficial ownership stake in Core Scientific (CORZ) through an amended Schedule 13G filing. This represents 16,956,009 shares of common stock, based on 321,340,441 shares outstanding as of July 23, 2026. …
Edwards Lifesciences Corp. (EW) stock fell 1.04% on Friday, closing at $91.60. This underperformance occurred on a generally negative trading day for the stock market, with both the S&P 500 Index and the Dow Jones Industrial Average also declining. The stock experienced its third …
Proficient Auto Logistics (PAL) reported a widened net loss of $10.4 million for the first half of 2026, compared to $4.7 million a year prior, with operating revenue slightly down to $203.1 million. Despite the loss, PAL closed a $130 million acquisition of Hansen …
An insider at Ciena Corporation (CIEN), David Rothenstein, has filed a Form 144 to sell 2,500 shares of common stock, valued at $1,106,975.00. These shares are related to Restricted Stock Units from 2021. The filing also notes previous 10b5-1 plan sales of 2,500 shares …
Ciena Corporation insider Marc Graff has filed a Form 144 notice to sell 4,995 shares of common stock, valued at $2,211,736.05. These shares are related to Restricted Stock Units acquired on August 1, 2026. The filing also details previous Rule 10b5-1 sales by Graff …
Paradigm BioCapital, along with its related entities and Senai Asefaw, M.D., has reported a collective beneficial ownership of 7.8% in Assembly Biosciences (ASMB), totaling 1,553,748 shares. This stake is based on an amended Schedule 13G filing, with Paradigm BioCapital International Fund Ltd. directly holding …
Twist Bioscience director Katryn Blake sold 2,240 shares of common stock on August 12, 2026, at $122.88 per share. This transaction was not a discretionary trade but was executed to cover tax liabilities arising from the vesting of Restricted Stock Units. Following the sale, …
A Schedule 13G/A filing indicates that Frazier Life Sciences-affiliated funds and individuals have updated their ownership report for Aura Biosciences (AURA). Frazier Life Sciences Public Fund, L.P. directly holds 5.6% of Aura Biosciences' common stock, and other Frazier funds also hold significant shares. The …
Vestal Point Capital, along with its Chief Investment Officer Ryan Wilder, has reported a beneficial ownership of 4.8% in Solid Biosciences Inc. (SLDB). This stake includes 4,833,796 common shares, of which 2,673,796 are issuable upon the exercise of pre-funded common stock purchase warrants. The …
Caribou Biosciences (NASDAQ:CRBU) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month price target of $7.75. The company's shares recently traded down 2.2% to $1.57. Caribou Biosciences reported a narrower-than-expected quarterly loss but missed revenue estimates, and institutional investors own …
Caribou Biosciences (NASDAQ: CRBU) reported second-quarter EPS of $-0.240, beating analyst estimates by $0.07, and revenue of $2.65 million, surpassing the consensus estimate of $2.3 million. Despite the earnings beat, the company's stock price has declined by -24.770% in the last three months and …
Satellos Bioscience Inc.'s average 12-month price target has been adjusted to $21.78, down from $22.04, according to estimates from 6 analysts. This new target suggests a potential upside of approximately 122% from the August 13 closing price. The consensus rating among 7 covering analysts …
Vestal Point Capital, LP and Ryan Wilder have filed an amended Schedule 13G, disclosing a 2.2% beneficial ownership in Alto Neuroscience, Inc., totaling 785,000 shares. These shares are held through a fund and a managed account advised by Vestal Point Capital, with both shared …
Jericho Capital Asset Management L.P. and Josh Resnick have reported a joint beneficial ownership of 22,882,942 shares of Core Scientific, Inc. common stock, which represents 7.2% of the class. They share both voting and dispositive power over these shares. This disclosure was made via …
Pentwater Capital Management LP and Matthew Halbower have disclosed a beneficial ownership of 1,336,594 shares of Core Scientific, Inc. common stock, representing 0.4% of the company's outstanding shares. This includes 800,000 shares issuable upon the exercise of options. All voting and dispositive authority over …
Achieve Life Sciences (ACHV) has established a $150 million at-the-market (ATM) equity offering program with Jefferies LLC as the sales agent. The company plans to sell common stock periodically, with net proceeds intended for the commercialization of cytisinicline, funding a Phase 3 clinical trial …
Jeremy Hayden, an insider at Sight Sciences (SGHT), filed a Form 144 indicating his intent to sell 48,000 shares of common stock on August 14, 2026, following a stock option exercise. The planned sale has an aggregate market value of $395,878.84. This filing also …
Schonfeld Strategic Advisors LLC has disclosed a 5.33% beneficial ownership stake in Inhibrx Biosciences, Inc. (INBX) through a Schedule 13G filing. This amounts to 781,678 shares of common stock, representing 5.33% of the 14,671,186 shares outstanding as of May 8, 2026. Schonfeld maintains sole …
Caligan Partners LP and David Johnson have reported a beneficial ownership stake of 5.9% in Cellectar Biosciences (CLRB), amounting to 469,998 shares. This ownership is held through Caligan-managed funds and accounts, with shared voting and dispositive power. The percentage is based on 7,991,812 shares …
Search by ticker symbol or company name and select a result to open its chart.